M. Sprick, J. Schwickert and F. Zickgraf discuss the identification of RAD51 as a biomarker of platinum resistance in High‐Grade Serous Ovarian Cancer patients, as reported by A. Jeyasekharan and colleagues in this issue of EMBO Molecular Medicine. Here, RAD51 is linked to ovarian carcinoma.